Business Overview: Zivo Bioscience, Inc. (OTC: ZIVO)

---

Executive Summary

Zivo Bioscience, Inc. is a research-and-development company operating at the intersection of biotech and agtech, built around proprietary algal and bacterial strains that the company has identified and cultivated for their inflammation-modulating and immune-boosting properties. The company's technology platform supports two parallel tracks: a therapeutic/biotech track, aimed at licensing bioactive extracts and molecules to larger animal-health and pharmaceutical partners after proof-of-concept work, and a nutrition/agtech track, selling a dried algae powder directly to consumers under the Zivolife brand.

Zivo is a small, pre-commercial-scale company: as of its most recent fiscal year end it had seven full-time employees and has conducted 23 clinical trials to date, with commercial Zivolife sales beginning in June 2023. It is not a shell company — it has real, ongoing R&D and limited commercial operations — but it is financially constrained, carrying a going-concern qualification from its auditor and an accumulated deficit of roughly $137.0 million.

Why it matters: Zivo represents the earliest, highest-risk end of the biotech value chain — a licensor of unproven biological discoveries rather than an owner of approved products — making it a useful illustration of how moat sources like intellectual property and switching costs can exist in nascent form long before a company has any meaningful revenue or regulatory approval to show for them.

---

1. Core Business Model & How They Work

Zivo's model is built on proprietary strains of algae and bacteria discovered and cultivated by the company, which it tests for bioactive, immune-modulating properties, then either (a) advances toward licensing deals with larger animal-health/pharma partners for therapeutic use, or (b) sells directly as a nutritional ingredient/powder.

 PROPRIETARY ALGAE/BACTERIA STRAINS (Zivo-owned biological IP)
                |
                v
     Lab research & clinical/field trials
     (poultry, bovine, canine, human indications)
                |
      -----------------------------------
      |                                 |
      v                                 v
 THERAPEUTIC TRACK                 NUTRITION TRACK
 Discovery-stage bioactives  --->  Dried algae powder ("Zivolife")
 Seek licensing deals with         Produced by contract manufacturer
 animal-health/pharma majors       Alimenta Algae (Peru)
 (e.g., poultry coccidiosis,             |
 avian influenza programs)               v
      |                           ZWorldwide, Inc. markets/
      v                           distributes, incl. direct-
 Licensing/milestone revenue      to-consumer online sales
 (not yet realized at scale)      (modest volumes to date)

Critically, Zivo itself does not run large-scale production or distribution — the nutrition side relies on a third-party contract manufacturer in Peru (Alimenta Algae) and a separate marketing/distribution entity (ZWorldwide, Inc.), while the therapeutic side is explicitly structured as a licensing play rather than an in-house drug-development-to-commercialization pipeline.

---

2. Business Segments

Zivo does not report formally separated reportable segments in its 10-K, but its operations naturally split into two distinct business lines that function differently enough to warrant separate discussion:

                    ZIVO BIOSCIENCE, INC.
                            |
          --------------------------------------
          |                                    |
   THERAPEUTIC / BIOTECH              NUTRITION / AGTECH
   (discovery-stage licensing)        ("Zivolife" brand)
          |                                    |
   - Poultry coccidiosis (lead)        - Dried algae powder,
   - Avian influenza (LPAI)              human food use
   - Bovine mastitis (early)           - Companion animal
   - Canine joint health (early)         ingredient extensions
   - Human immune modulation           - Possible skin-health /
     (discovery stage)                   New Dietary Ingredient
                                          filing

• Therapeutic (biotech): The more strategically important track, centered on the lead poultry coccidiosis candidate (a non-antibiotic immune modulator for broiler chickens, over which the USDA's Center for Veterinary Biologics has claimed jurisdiction), plus an avian influenza proof-of-concept and earlier-stage work in bovine mastitis, canine joint health, and human immune modulation. All of these remain discovery-stage; none has generated licensing revenue at scale.
• Nutrition (agtech): The commercial-stage track, selling Zivolife algae powder since June 2023, though the company itself describes sales volumes as "relatively low."

---

3. Key Offerings

---

4. Competitive Landscape

Zivo competes across several distinct, mostly unrelated categories given its platform's many applications:

• Poultry & avian influenza health: HuvePharma, Elanco, Zoetis, Phibro — large, well-capitalized animal-health companies with established manufacturing, regulatory, and distribution infrastructure that Zivo lacks; Zivo's strategy is to license to, rather than compete head-on with, players like these.
• Bovine mastitis: ToDay™, Masti-Clear, Lysigin, Spectramast LC™, among others — established branded treatments with incumbency in dairy operations.
• Canine joint health: Boehringer Ingelheim, Zoetis, Merck Animal Health, Elanco, Bayer AG, and others — large animal-health franchises with existing veterinary relationships.
• Human immune modulation: Eritoran (Eisai) and Resatorvid (Takeda), both TLR4 inhibitors — pharma-grade candidates from companies with vastly greater R&D and regulatory resources.
• Human food/nutrition: Earthrise, Cyanotech, AG1, plus large food-ingredient players such as DSM, Cargill, and Nestle — Zivolife competes in a crowded algae/superfood supplement category against both niche brands and ingredient majors.

In every category, Zivo's practical competitive strategy is to be acquired or licensed by a larger incumbent rather than to out-compete on scale or distribution.

---

5. Strategic Strengths & Risks

Strengths (moat sources):

• Proprietary biological strains and know-how: Zivo's algae/bacteria strains and associated cultivation and extraction techniques represent genuine, hard-to-replicate intellectual property, built up over many years and 23 clinical trials.
• First-mover discovery work in several under-explored therapeutic niches (e.g., antibiotic-free poultry immune modulation), which could command licensing value if validated.

Risks:

• Going concern: The auditor's going-concern qualification reflects genuine, material doubt about the company's ability to continue operating without further financing.
• Financing dependence: The company has restructured convertible debt (roughly $240,000 into notes totaling $277,254 in November 2024) and will likely need further dilutive financing to fund operations and trials.
• Discovery-stage risk across the therapeutic pipeline: None of the therapeutic candidates has reached commercial licensing; regulatory jurisdiction questions (e.g., USDA oversight of the poultry candidate) add uncertainty.
• Peru manufacturing concentration: The nutrition business depends on a single contract manufacturer (Alimenta Algae) in Peru, exposing it to political, regulatory, and tariff risk in that single location.
• Agricultural production risk: Algae cultivation is exposed to weather, contamination, and water availability.
• Low commercial sales to date: Zivolife volumes remain low, meaning the one revenue-generating product line is not yet a meaningful offset to R&D cash burn.

---

6. Financial Overview

---

7. Summary Conclusion

Zivo Bioscience is a genuine, if very small, operating biotech/agtech company whose value proposition rests on proprietary algae- and bacteria-derived bioactive compounds rather than on scale, brand, or distribution. Its two-track strategy — licensing therapeutic discoveries to larger animal-health and pharma partners while selling a modest nutritional product directly — reflects a sensible way for a cash-constrained R&D company to pursue both near-term revenue and longer-dated licensing upside. That said, the company's going-concern qualification, heavy reliance on future financing, and discovery-stage status across its therapeutic pipeline mean the investment case depends almost entirely on clinical and licensing milestones (such as the December 2024 avian influenza proof-of-concept) converting into real partner deals before the company's cash runway and dilution tolerance run out.